← Back to Search

Somatostatin Analog

Y-90 microspheres for Neuroendocrine Tumors

Phase 2
Waitlist Available
Research Sponsored by SCRI Development Innovations, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 12 weeks post-treatment with sir-spheres then every 8 weeks, up to 52 months
Awards & highlights

Study Summary

This study is evaluating whether a combination of two treatments can improve the survival of patients with NETs.

Eligible Conditions
  • Neuroendocrine Tumors
  • Gastrointestinal Tumors
  • Carcinoid Tumor

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 12 weeks post-treatment with sir-spheres then every 8 weeks, up to 52 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 12 weeks post-treatment with sir-spheres then every 8 weeks, up to 52 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability
Secondary outcome measures
Disease Control Rate
Overall Response Rate
Overall Survival
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Lanreotide/Y-90 microspheresExperimental Treatment2 Interventions
Lanreotide: 120 mg by subcutaneous injection (SQ) on Day 1 of every cycle (every 28 days) in combination with SIR-Spheres therapy. Y-90 (Yttrium-90) microspheres [SIR-Spheres therapy]: dose and treatment day to be determined by treating radiation oncologist.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lanreotide
2009
Completed Phase 3
~600

Find a Location

Who is running the clinical trial?

SCRI Development Innovations, LLCLead Sponsor
191 Previous Clinical Trials
13,557 Total Patients Enrolled
IpsenIndustry Sponsor
345 Previous Clinical Trials
73,222 Total Patients Enrolled
34 Trials studying Neuroendocrine Tumors
2,998 Patients Enrolled for Neuroendocrine Tumors
David Spigel, M.D.Study ChairSCRI Development Innovations, LLC
7 Previous Clinical Trials
675 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
2017. "Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02859064.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top